Voya Investment Management LLC Has $7.26 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Voya Investment Management LLC decreased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 300,284 shares of the company's stock after selling 31,830 shares during the quarter. Voya Investment Management LLC owned approximately 0.14% of Hims & Hers Health worth $7,261,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after acquiring an additional 40,447 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Hims & Hers Health by 7.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock valued at $43,448,000 after acquiring an additional 129,416 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity

In other news, insider Soleil Boughton sold 4,153 shares of the company's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $35.30, for a total transaction of $146,600.90. Following the completion of the sale, the insider now directly owns 161,497 shares of the company's stock, valued at $5,700,844.10. This represents a 2.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Irene Becklund sold 2,203 shares of Hims & Hers Health stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the completion of the transaction, the insider now directly owns 8,007 shares in the company, valued at $230,441.46. This represents a 21.58 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 666,234 shares of company stock worth $26,387,645. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Up 13.3 %

Hims & Hers Health stock traded up $4.82 during trading hours on Friday, hitting $40.98. 49,512,288 shares of the company traded hands, compared to its average volume of 16,802,829. The firm's 50-day simple moving average is $32.21 and its two-hundred day simple moving average is $31.49. The firm has a market cap of $9.10 billion, a P/E ratio of 93.14 and a beta of 1.65. Hims & Hers Health, Inc. has a 1-year low of $11.45 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Truist Financial lowered their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Citigroup lowered their price objective on shares of Hims & Hers Health from $27.00 to $25.00 and set a "sell" rating for the company in a research report on Friday, April 25th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and cut their target price for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Morgan Stanley lowered their target price on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a report on Tuesday, April 29th. Finally, Bank of America increased their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $36.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.